These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32810886)

  • 1. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies.
    Hamadeh A; Haines A; Feng Z; Thein HH; Janjua NZ; Krahn M; Wong WWL
    J Viral Hepat; 2020 Dec; 27(12):1419-1429. PubMed ID: 32810886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
    Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
    Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of COVID-19 Period Prevalence and the Undiagnosed Population in Canadian Provinces: Model-Based Analysis.
    Hamadeh A; Feng Z; Niergarth J; Wong WW
    JMIR Public Health Surveill; 2021 Sep; 7(9):e26409. PubMed ID: 34228626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
    Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
    EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
    Poovorawan K; Pan-Ngum W; White LJ; Soonthornworasiri N; Wilairatana P; Wasitthankasem R; Tangkijvanich P; Poovorawan Y
    PLoS One; 2016; 11(9):e0163095. PubMed ID: 27631382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
    Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ
    Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease burden of chronic hepatitis C among immigrants in Canada.
    Chen W; Krahn M
    J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model-based framework for chronic hepatitis C prevalence estimation.
    Hamadeh A; Feng Z; Krahn M; Wong WWL
    PLoS One; 2019; 14(11):e0225366. PubMed ID: 31751393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
    Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
    BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
    Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
    J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care.
    Socías ME; Shannon K; Montaner JS; Guillemi S; Dobrer S; Nguyen P; Goldenberg S; Deering K
    Can J Gastroenterol Hepatol; 2015; 29(8):411-6. PubMed ID: 26492129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
    Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
    J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.
    Binka M; Butt ZA; Wong S; Chong M; Buxton JA; Chapinal N; Yu A; Alvarez M; Darvishian M; Wong J; McGowan G; Torban M; Gilbert M; Tyndall M; Krajden M; Janjua NZ
    World J Gastroenterol; 2018 Mar; 24(11):1216-1227. PubMed ID: 29568202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
    J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study.
    Tsui TCO; Zeitouny S; Bremner KE; Cheung DC; Mulder C; Croxford R; Del Giudice L; Lapointe-Shaw L; Mendlowitz A; Wong WWL; Perlis N; Sander B; Teckle P; Tomlinson G; Walker JD; Malikov K; McGrail KM; Peacock S; Kulkarni GS; Pataky RE; Krahn MD
    CMAJ Open; 2022; 10(3):E818-E830. PubMed ID: 36126976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis.
    Söderholm J; Millbourn C; Büsch K; Kövamees J; Schvarcz R; Lindahl K; Bruchfeld A
    J Hepatol; 2018 May; 68(5):904-911. PubMed ID: 29233630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
    Northcott MJ; Ong WL; Walsh M; McCarthy P; Belleli D; Tran H; Street A; Kemp W; Davis AK
    Haemophilia; 2013 Nov; 19(6):847-52. PubMed ID: 23738855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.